Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Aquestive Therapeutics To Contact Him Directly To Discuss Their Options If you suffered significant losses in Beta Bionics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Feb. 15, 2026 (GLOBE NEWSWIRE) -- Faruqi ...

The market expects Beta Bionics, Inc. (BBNX) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on February 17, might help the stock move higher if these key number ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Aquestive Therapeutics, Inc. (Beta Bionics) due to significant stock losses and possible misleading statements made by the company [2][3]. Company Investigation - The investigation centers on whether Beta Bionics issued misleading statements or failed to disclose important information to investors [3]. - Following the announcement of fewer patient starts than analysts estimated for the fourth quarter, Beta Bionics' shares dropped approximately 37% on January 9, 2026 [3]. Legal Options for Investors - Investors who suffered significant losses in Beta Bionics stock or options are encouraged to contact Faruqi & Faruqi to discuss their legal rights and options [1][4].

NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Beta Bionics and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Aquestive Therapeutics, Inc. (Beta Bionics) due to significant stock losses and possible misleading statements made by the company [2][5]. Group 1: Company Overview - Aquestive Therapeutics, Inc. is also referred to as Beta Bionics and is listed on NASDAQ under the ticker BBNX [2]. - The company has experienced a significant decline in its stock price, with shares plunging approximately 37% on January 9, 2026, following an announcement regarding fewer patient starts than analysts had estimated for the fourth quarter [5]. Group 2: Legal Investigation - The investigation by Faruqi & Faruqi focuses on whether Beta Bionics issued misleading statements or failed to disclose important information that could affect investors [5]. - Investors who have suffered significant losses in Beta Bionics stock or options are encouraged to contact the law firm to discuss their legal rights [1].

Core Insights - Holzer & Holzer, LLC is investigating whether Beta Bionics, Inc. complied with federal securities laws following the announcement of preliminary fourth quarter 2025 financial results, which indicated that new patient starts for the iLet Bionic Pancreas System are expected to be below analyst estimates [1] Company Summary - Beta Bionics, Inc. (NASDAQ: BBNX) reported that new patient starts for its iLet Bionic Pancreas System are anticipated to fall short of analyst expectations for the fourth quarter of 2025 [1] - The announcement led to a decline in the company's stock price [1]

Core Insights - Beta Bionics experienced a significant decline in stock price following the release of preliminary fourth-quarter 2025 performance metrics that did not meet market expectations [1] - The company reported lower-than-expected new patient starts for its iLet automated insulin delivery system, raising concerns among investors about short-term adoption trends and revenue growth [1] - On January 9, 2026, Beta Bionics' stock fell approximately $11.85, or 37.04%, closing at $20.14 [1]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Beta Bionics, Inc. due to significant stock losses and possible misleading statements made by the company [4][5]. Group 1: Company Overview - Beta Bionics, Inc. is listed on NASDAQ under the ticker BBNX [4]. - The company experienced a significant stock price decline of approximately 37% on January 9, 2026, following an announcement regarding lower-than-expected patient starts for the fourth quarter [5]. Group 2: Legal Investigation - The investigation by Faruqi & Faruqi focuses on whether Beta Bionics issued misleading statements or failed to disclose important information relevant to investors [5]. - Faruqi & Faruqi has a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [4].

NEW YORK, Jan. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Beta Bionics, Inc. ("Beta Bionics" or the "Company") (NASDAQ: BBNX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Beta Bionics and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On January ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Aquestive Therapeutics, Inc. (Beta Bionics) due to significant stock losses following a disappointing earnings announcement [2][5]. Group 1: Company Overview - Aquestive Therapeutics, Inc. is also referred to as Beta Bionics and is listed on NASDAQ under the ticker BBNX [2]. - The company experienced a significant decline in its stock price, with shares plunging approximately 37% on January 9, 2026, after announcing expectations of fewer patient starts in the fourth quarter than analysts had estimated [5]. Group 2: Legal Investigation - The investigation by Faruqi & Faruqi focuses on whether Beta Bionics issued misleading statements or failed to disclose important information that could affect investors [5]. - Investors who suffered significant losses in Beta Bionics stock or options are encouraged to contact the law firm to discuss their legal rights [1].